$COYA News

Coya Therapeutics secures FDA fast track status for COYA 302

Coya Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Coya Therapeutics Has Been Granted U.S. FDA Fast Track Designation for COYA 302 for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

Coya Therapeutics Launches $30M At-The-Market Stock Offering Agreement With Leerink Partners

Coya Therapeutics Q1 EPS $(0.32) Beats $(0.41) Estimate, Sales $251.147K Beat $125.000K Estimate

Coya Therapeutics Says FDA Grants Fast Track Designation For COYA 302, Proprietary Investigational Biologic Combination Therapy With Dual Mechanism Of Action, For ALS Treatment

NanoViricides to Participate at D. Boral Capital Global Conference in NYC

NanoViricides’ Measles Treatment Granted Orphan Drug Designation by FDA

Coya Therapeutics shares are trading higher after the company announced a publication demonstrating that COYA 302 increased three biomarkers in ALS patients compared to controls.

Coya Therapeutics shares are trading higher after the company announced a publication demonstrating that COYA 302 increased three biomarkers in ALS patients compared to controls.

Coya Therapeutics Announces Publication Demonstrating Correlation Between Longitudinal Biomarker Data and Clinical Outcomes Supporting the Mechanistic Rationale for COYA 302 in Patients with ALS

Coya Therapeutics Announces Publication Demonstrating That COYA 302 Increased Three Biomarkers In ALS Patients Compared To Controls

Coya Therapeutics Announces Planned Board Transition and Appointment of Mark H. Pavao as Independent Director

HC Wainwright & Co. Reiterates Buy on Coya Therapeutics, Maintains $18 Price Target

Coya Therapeutics Announces Publication Demonstrating Regulatory T-Cell Dysfunction and Systemic Inflammation in Frontotemporal Dementia, Supporting Mechanistic Rationale for COYA 302 Immune-Restoring Therapy

Coya Therapeutics Announces The Publication Of A Research Study Demonstrating The Involvement Of The Peripheral Immune System In The Neuroinflammatory Profile Of Frontotemporal Dementia (FTD)

Coya Therapeutics Q4 EPS $(0.34) Misses $(0.28) Estimate, Sales $3.960M Beat $1.928M Estimate

Coya Therapeutics Provides a Corporate Update and Reports Fiscal 2025 Financial Results

Coya Therapeutics Files Prospectus To Register Resale Of 2,522,727 Common Shares Issued In Private Placement

Coya Therapeutics, Inc. (COYA) Upgraded to Buy: What Does It Mean for the Stock?